BioPharm International

BioPharm International-02-01-2005
Volume: 18
Issue: 2

BioPharm International-01-01-2005
Volume: 18
Issue: 1

BioPharm International-12-01-2004
Volume: 17
Issue: 12

BioPharm International-11-15-2004
Volume: 2004 Supplement
Issue: 5

BioPharm International-11-01-2004
Volume: 17
Issue: 11

BioPharm International-10-15-2004
Volume: 2004 Supplement
Issue: 4

BioPharm International-10-01-2004
Volume: 17
Issue: 10

BioPharm International-09-01-2004
Volume: 17
Issue: 9

BioPharm International-09-15-2004
Volume: 2004 Supplement
Issue: 3

BioPharm International-08-01-2004
Volume: 17
Issue: 8

BioPharm International-08-15-2004
Volume: 2004 Supplement
Issue: 2

BioPharm International-07-01-2004
Volume: 17
Issue: 7

BioPharm International-06-01-2004
Volume: 17
Issue: 6

BioPharm International-05-01-2004
Volume: 17
Issue: 5

BioPharm International-04-01-2004
Volume: 17
Issue: 4

BioPharm International-03-01-2004
Volume: 17
Issue: 3

BioPharm International-02-01-2004
Volume: 17
Issue: 2

BioPharm International-02-15-2004
Volume: 2004 Supplement
Issue: 1

BioPharm International-01-01-2004
Volume: 17
Issue: 1

BioPharm International-12-01-2003
Volume: 16
Issue: 12

BioPharm International-11-15-2003
Volume: 2003 Supplement
Issue: 4

BioPharm International-11-01-2003
Volume: 16
Issue: 11

BioPharm International-10-01-2003
Volume: 16
Issue: 10

BioPharm International-09-01-2003
Volume: 16
Issue: 9

BioPharm International-09-15-2003
Volume: 2003 Supplement
Issue: 3

BioPharm International-08-01-2003
Volume: 16
Issue: 8

BioPharm International-07-01-2003
Volume: 16
Issue: 7

BioPharm International-07-15-2003
Volume: 2003 Supplement
Issue: 2

BioPharm International-06-01-2003
Volume: 16
Issue: 6

BioPharm International-06-02-2003
Volume: 2003 Supplement
Issue: 1
Advertisement
Advertisement
Trending on BioPharm International
1
Biocon’s Pebrilzo Becomes First Breast Cancer Treatment Biosimilar Approved Under EMA’s Tailored Clinical Approach
2
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
3
AbbVie and DISCO Partner on AND-Gated Bispecifics Designed to Recognize Tumor-Selective Protein Pairs
4
FDA Approves First RNAi Therapeutic for Generalized Myasthenia Gravis
5

